Drug Profile
Research programme: pathogen extracting therapies - Opsonix
Alternative Names: FcMBL - OpsonixLatest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Harvard University; Opsonix
- Class Immunoglobulin Fc fragments; Recombinant proteins
- Mechanism of Action Immunostimulants; Mannose binding lectin modulators; Pattern recognition receptor agonists; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Infections; Sepsis
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Infections in USA (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Sepsis in USA (unspecified route)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Infections in USA